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Abstract 
Antibodies against donor HLA determine access to solid organ transplantation and in many 
cases the outcome of transplantation, but graft failure is not an inevitable consequence of 
their presence. Much research has been performed with two main aims – which antibodies 
represent the highest risk factor prior to transplantation, and second to understand how 
donor specific HLA antibodies behave after transplantation, with a long-term aim of being 
able to manipulate their production. HLA antibody incompatible kidney transplantation is 
the best model for examining antibody responses and this review looks at methods for 
interrogating the antibodies using ‘traditional’ snapshot techniques such as cytoxicity testing, 
and newer dissection techniques such as antibody subclass, complement binding and 
activity and affinity. Integral to the understanding of the large datasets generated is 
sophisticated mathematical analysis using techniques such as decision tree analysis and 
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unsupervised machine learning. This review examines key aspects of this work, performed 
by us and others. 
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1. Introduction 
Kidney transplantation is the optimal treatment for patients with end stage kidney disease but 
immunological barriers, especially HLA antibodies, are important factors limiting timely 
accessibility to transplantation. Assays detecting and defining HLA antibodies have evolved over 
the last few decades. This has allowed us to better understand humoral responses but has posed a 
major challenge in defining threshold at which we can safely transplant, as we are now detecting 
antibodies at very low levels with increasing sensitivity and specificity. This has redrawn the risk 
stratification in decision making but also increased complexities. Additionally, over the last two 
decades, transplantation across blood group and HLA antibody incompatibilities have been 
performed successfully in different parts of the world [1-7] using varied desensitisation therapies 
[8]. This is partly due to improvements in diagnostic techniques such as HLA tissue typing, 
identification of HLA-specific antibodies, crossmatch techniques [9] and advances in therapeutic 
approaches such as adsorption columns [10], removal of antibodies by plasmapheresis [11, 12], 
and newer biological therapies. Data from transplanted series tend to stratify results based on 
positive response in current assays, but none of the assays can accurately predict long-term 
clinical outcomes irrespective of desensitisation protocol utilised. Hence efforts have been made 
to characterise and analyse other properties of antibodies and the underlying regulatory 
mechanisms. This review summarises current literatures surrounding HLA-specific antibodies and 
outcome of HLA-incompatible kidney transplantation across the range of immunological risks. 
2. Snapshot: Current Assays Used in Laboratories and Relation to Clinical Outcome 
Three main assays are widely used to risk stratify donor specific antibodies (DSA) risks prior to 
HLA-incompatible kidney transplantation. Two of these are cellular assays (complement 
dependent cytotoxicity and flow cytometry), and the third one is solid phase luminex assay using 
microbeads coated with HLA proteins. The relationship between the three assays is shown in 
Figure 1. As the assays measure a different aspect of antibody binding, there is incomplete 
concordance between the results obtained. Microbead (luminex) assay is highly sensitive and is 
specific for HLA proteins. Low levels of HLA-specific antibodies are detected that may not give a 
positive signal on flow cytometry or CDC. Both flow cytometry and CDC assays use lymphocytes to 
study the binding of antibodies, but the principle differs from each other such that one studies 
complement fixing antibodies whereas other tests both complement fixing and non-complement 
fixing antibodies. Anti-human globulin (AHG) augmented CDC can detect non-complement fixing 
antibodies too, thus more sensitive compared to non-augmented CDC assay. However, the value 
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of a more sensitive CDC assay might be re-evaluated given the availability of flow cytometry and 
luminex bead assay and recent long term clinical outcome data.  
 
Figure 1 Overlap of current assays used in determining HLA-specific antibodies. 
It has generally agreed that selective responses of patient sera with above three assays can 
quantify strength of antibodies, with positive results for all three assays the most powerful and 
luminex assay alone positive at milder end of the spectrum. The microbead assay is also very 
important in defining positive CDC results that are not due to HLA antibodies and may not be 
clinically significant. Analysis of outcome from 114 HLA-incompatible kidney transplantation at our 
centre showed early antibody mediated rejection (within 30 days post transplantation) was higher 
in CDC (55%; N = 12/22) followed by flow positive group (50%; N=28/57) and least in luminex bead 
positive alone (23%; N=8/35). This was statistically significant (Figure 2A). The crossmatch status 
also influenced treatment success following an episode of early acute antibody mediated rejection 
(AAMR). At our centre, we have observed 100 % recovery of graft function at three months post 
episode of AAMR in non-CDC group (N=39/39) compared to 80% in CDC group (N=12/15), p = 0.4 
[13]. 
 
Figure 2 Outcomes following HLA-incompatible kidney transplantation in relation to 
current assays; A – early AAMR and B – death censored graft survival (Kaplan Meier 
survival analysis and statistics by log rank test).  
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Previously we have shown that five-year death censored graft survival following HLA-
incompatible kidney transplantation are 78 %, 80 % and 54 % in groups with luminex bead assay 
alone positive, luminex and flow XM positive but CDC negative, and CDC (non-AHG) positive 
groups, respectively [2]. A recent analysis of 114 HLA-incompatible kidney transplantation at our 
centre revealed that patients with CDC positive continue to have worse graft survival, with death 
censored graft survival at eight-year reduced to 40%, whilst other two groups remained stable 
(Figure 2B). Similar findings were observed in a multicentre data evaluation in USA [7], which 
showed an unadjusted five-year graft survival of 80%, 71% and 60 % for group with luminex alone 
positive, luminex and flow XM positive but CDC negative and CDC (AHG) groups respectively.  
Thus, many centres use risk stratification based on positive results obtained on the above three 
assays, with CDC positive at the highest risk and luminex microbead alone at lower risk and flow 
crossmatch at intermediate risk for poor outcome. In UK, living transplant pairs with higher titre 
CDC positive results on crossmatch are discouraged for direct transplantation, which is reserved 
for exceptional situations such as failing dialysis access or increasing recipient co-morbidities.  
Although CDC positivity prior to transplantation is associated with poor outcome, this is not 
universal as one in two direct transplants across a positive CDC result has good outcome (both 
early antibody mediated rejection and longer-term graft survival), and low titre CDC positive 
transplants have good results in our series. On the other hand, pre-transplant flow cytometer 
crossmatch or luminex positive alone have equivalent outcomes as compatible kidney 
transplantation [2]. Patients with class I HLA-specific and multiple DSA antibodies giving CDC 
positive are associated with worse outcomes.  
3. MFI Value of HLA-Specific Antibodies 
With the advent of microbead luminex assay, laboratories are utilising this sensitive and 
specific assay for DSA risk stratification. Is MFI value-based stratification as good as CDC? 
Preliminary studies at our centre using multivariate analysis on pre-transplant variables such as 
IgG, IgG sub-classes and CDC showed that CDC was not an independent predictor of rejection or 
graft failure [14]. It should be noted that this outcome was obtained within our envelope for 
accepting risk, i.e., we transplanted some patients with a high titre of DQ or DP antibodies, but did 
not transplant patients with high CDC titres of Class 1 or DR antibodies (roughly 1:16 or greater). 
We have previously shown that a higher MFI value on luminex bead assay is correlated with worse 
graft survival (Figure 3) [2]. An MFI value (non-EDTA) of 3000 pre-transplantation is associated 
with a lower risk of AAMR; however early AAMR in patients who were CDC negative, pre-
treatment does seem to be a treatable condition in our series, and 5-10 year outcomes are more 
important clinically [15].  




Figure 3 Death censored graft survival and MFI values of donor HLA-specific antibodies 
(adapted from Higgins et al [2]). 
A genuinely low value of MFI pre-transplantation can give false reassurance, and amnestic 
response following HLA-incompatible kidney transplantation is seen associated with AAMR. We 
have shown that the MFI values can go low as time goes by, at times below the clinical threshold 
and on re-stimulation of epitope/antigen can trigger rapid rise of antibody levels and this may vary 
on initial sensitisation event, with pregnancy related sensitisation more important than prior 
transplantation or blood transfusion [16]. There is a higher proportion of cases with highest 
percentage rise in MFI values compared to baseline in patients undergoing HLA-incompatible 
kidney transplantation from pregnancy related sensitisation as a spouse or child donor compared 
to other sensitisation events (Figure 4). Various approaches are proposed to reduce sensitisation 
such eplet matching strategies [17] judicious use of blood products in patients with kidney disease 
and, avoiding graft nephrectomy and maintaining low dose immunosuppressive medications after 
transplant failure [18]. 
 
Figure 4 Percentage rise of HLA-specific antibodies following HLA-incompatible kidney 
transplantation related to sensitisation events. Rise in MFI values are divided in four 
strata of rise - <100 %, 100 to 500 %, 500 to 1000% and > 1000% rise from baseline.  
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MFI values obtained from the binding of HLA-specific antibodies on luminex assay are 
sometimes used quantitatively, but the assay readout is a composite of both concentration and 
affinity of the HLA-specific antibodies [19]. The binding of antibodies to the solid phase assays is 
influenced by the affinity of the antibodies. Hence, low affinity antibodies could be washed away 
in multi-wash steps during the procedure to get rid of non-specific adsorption to the beads. Also, if 
the antibodies are tested on single antigen beads, then the antibodies bind to a number of specific 
beads due to shared epitope and if present in low concentration, could give false negative result 
against the ‘primary’ target HLA but a crossmatch can still be positive [20]. Using purified human 
monoclonal HLA-specific antibodies, we have shown that MFI values are affected by both the 
affinity and concentration of the antibodies and thus a product of two distinct characteristics - the 
higher affinity suggesting further steps in humoral maturation [19, 21].  
A very high concentration of antibodies can sometimes give a false low binding response due to 
competition for binding space; this is called hook effect [22], or prozone effect. This can be 
overcome by repeating the test with a dilution of sample, or treatment with EDTA [23]. This 
interference could be due to the presence of C1q molecule interfering binding of fluorescence 
conjugated detecting antibodies [24]. Although most laboratories are now using EDTA, correlation 
with long term outcomes is not yet fully defined with this assay. It is also important to note that 
MFI values and Luminex testing have intra and inter-centre variation [25] which limits comparisons 
of outcome studies. Studies have demonstrated certain risk factors that are associated with poor 
outcome following antibody incompatible transplantation (Table 1) but it is important that these 
are not good in evaluating risks precisely. 
Table 1 Risk factors for rejection and graft loss in HLA-incompatible kidney 
transplantation (adapted from Montgomery et al [26] and others such as * Higgins et 
al [15], ** Higgins et al [16], *** Vo et al [27], **** Senev et al [28]). 
Wide breadth of HLA reactivity 
Previous transplants*** 
Previous early graft losses 
Sustained antibody production to all or most previous mismatched antigens 
Multiple repeat mismatches (spreading specificities during rejection) 
Eplet mismatch load, particularly at HLA-DQ**** 
Multiple donor specific antibodies * 
Multiple sensitising events 
High risk combinations (husband-to-wife or child-to-mother transplants) ** & *** 
4. Granular Characterisation of HLA-Specific Antibodies: Reasons for Varied Clinical Outcome 
and Newer Approaches for Risk Stratification 
We have observed varied graft responses in the presence of donor HLA-specific antibodies 
(Figure 5): in some instances causing acute rejection, and in other instances existing with perfectly 
functioning grafts or the resolution of rejection in the presence of high levels of antibodies [29, 30]. 




Figure 5 Variable graft response to donor HLA-specific antibody (DSA). (A) Cases who 
developed graft rejection accompanied with the rise of DSA, then a resolution of 
rejection and fall in DSA and (B) Cases whose graft functioned perfectly normally in the 
period of observation despite a steep rise and falls, in some with plateau of DSA 
(despite plasmapheresis as seen in dip of levels). All cases with AMR received Anti-
thymoglobulin (ATG) treatment but otherwise cases in both groups treated similarly. 
(adapted from Zhang et al. [30]). 
These variable responses could be due to antibody-specific factors, donor kidney and/or host-
specific responses; therapy is also a possible factor. Although the mechanisms underlying these 
variable responses are complex, it is important to note that the mere presence or absence of 
antibodies does not determine adverse events. There is a change either in the immunological 
milieu or graft environment, or in the characteristics of these antibodies that determine 
immunological response and graft fate. Various parameters of antibodies have been studied by 
different groups, and the findings are summarised below.  
4.1 Complement Activation Ability 
Complement activation following the binding of antibodies to the HLA antigens on endothelial 
cells is considered one of the most potent mechanisms for antibody mediated rejection. This may 
occur through cytotoxicity generated directly or with the help of effector cells, including 
neutrophils, macrophages and T cells. Though the benefit of reducing AAMR by complement 
blockade at the time of transplant was limited to complement activating DSA and not from non-
complement activating antibodies [31]. 
Data from CDC assay suggest complement fixation is associated with rejection, but CDC is not a 
specific assay for HLA-specific antibodies. Studies using a C1q binding assay protocol showed that 
the presence of C1q fixing antibodies is associated with worse graft function [32, 33]. Study by 
Loupy et al has shown that C1q positivity, in addition to DSA specificity, is associated with graft 
outcome [32]. Additionally, they showed that conversion of C1q negative DSA to positive post-
transplantation was associated with worse outcomes. Additional testing of C1q binding ability may 
stratify the DSA risk further. However, the usefulness of C1q binding has not been uniformly 
reproduced in other studies [34-38]. The limitations of the C1q assay is probably related to its 
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correlation with IgG DSA MFI as the C1q positivity is a mere reflection of higher IgG MFI levels [39]. 
Also, C1q positivity could be due to the binding of IgM antibodies. The complement activating 
properties of HLA-specific antibodies can also be assessed using complement C3 split product, C3d, 
which is further downstream in the complement pathway, and this may overcome some of the 
limitations of C1q assay [40]. In our multicentre cohort, 139 highly sensitized patients with positive 
crossmatch who underwent HLA antibody incompatible renal transplantation were studied for C3d 
binding. As depicted in Figures 6a and 6b, presence of C3d-positive DSA in pre-transplant and 
post-transplant periods were associated with worse renal allograft survival [41].  
 
Figure 6 Kaplan Meier survival analysis: death censored graft survival was significantly 
worse in patients with pre-transplant C3d positive DSA (A) and with persistent C3d 
positive DSA compared to C3d negative pre- and post-transplant patients (B) (adapted 
from [41]). 
In this multicentre cohort study [41], C3d assay was able to clearly define groups with better 
outcome among moderate to high immunological risk (flow and CDC positive) cases. Cases with 
pre-treatment C3d-negative DSAs are likely to have a good result at five years, whether the 
reactions become C3d-positive or not at around day 14. The best survival is seen in patients with 
C3d-negative DSA at both pre-treatment and day 14. 
A single centre study of 68 highly sensitized patients that included 21 CDC crossmatch positive 
patients looked at pre-treatment risk stratification using in-vitro C4d deposition on SAB. Presences 
of pre-transplant C4d+DSA were associated with acute AMR. One, three and five-year death 
censored graft survival was also significantly lower in the C4d positive DSA patients than in C4d 
negative DSA patients [42]. Other studies have shown that in crossmatch negative sensitised 
patients, DSAs with complement activating potential, measured by C1q binding at the time of 
transplantation and/or post-transplantation, are also associated with poor renal allograft survival 
[32, 43, 44]. A large study by Kamburova et al concluded that the presence of pre-transplant C3d-
positive DSAs was associated with reduced renal allograft survival but did not reach statistical 
significance [45]. Post-transplant development of complement activating DSA has also been shown 
to be a risk factor in paediatric renal transplantation [46, 47]. 
Two comparable studies have indicated that testing for complement activating DSA at the time 
of AMR predicts graft survival using C1q binding and C3d activating assays, respectively [32, 40]. 
Similarly, a recently published study from the deteriorating kidney allograft function (DeKAF) 
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investigators, in a cohort of standard renal transplants, the results of a C3d assay performed at the 
time of development of DSA and graft dysfunction, predicted a higher risk of graft failure in C3d-
positive DSA group compared to C3d negative DSA group [48]. 
4.2 Correlation of Complement-Fixing/Activating Antibodies with Crossmatch 
It is established that complement activating antibodies, as detected by complement-dependent 
cytotoxicity crossmatch, are associated with worse graft survival [9]. However, the CDC assay is 
not always specific and can identify other non-HLA complement activating antibodies [49, 50], so 
current practice is to regard a positive CDC test as relevant when microbead testing confirms the 
presence of DSA. The availability of viable donor cells still limits the CDC assay, and it is not always 
practical to perform this assay on multiple occasions in the pre-transplant and post-transplant 
periods. In recently published single-centre studies, positive C3d assay was shown to correlate 
with high specificity, and a positive predictive value with a positive FC crossmatch, although 
sensitivity and negative predictive value were low [51, 52]. A negative C3d assay had a higher 
negative predictive value for CDC; this could be a useful surrogate marker for risk stratification as 
a negative CDC crossmatch is generally required at the time of transplantation. The flow 
cytometry crossmatches, although more sensitive than CDC, have similar limitations. Typically, a 
positive pre-transplantation crossmatch is discouraged due to the high risk of rejection [53] and 
reduced graft survival [2, 54]. In the subgroup analysis of FC crossmatch patients, pre-treatment 
C3d-positive DSA was associated with lower graft survival. This finding is not entirely surprising as 
in one of the earlier studies that looked at the utility of C4d-positive DSA in a cohort of highly 
sensitized patients, the presence of pretransplant C4d positive DSA in CDC crossmatch patients 
were associated with worse graft survival compared to the C4d-negative cohort [55].  
4.3 Class and Subclass Switching 
As the immune response progresses with time, there is a class switch whereby the Fc portion of 
the antibodies are altered, resulting in structural and functional change. IgG HLA-specific 
antibodies can be of different sub-classes (IgG1-4), and the current assay gives a composite 
readout at the IgG level. We have shown significant heterogeneity of IgG subclasses in cases with 
pre-formed HLA-specific antibodies [56]. Different IgG subclass differs in its ability to bind to 
complement and hence complement activations; IgG1 and IgG3 are strong complement activating 
followed by IgG2. Hence many studies have explored the subclass profiles and related them to the 
outcome of HLA-incompatible kidney transplantation. 
Earlier studies on pre-formed HLA-specific antibodies had contradictory findings [57, 58]. 
Recently, we have shown that IgG4 sub-class presence prior to transplantation is independently 
associated with poor outcome, namely antibody mediated rejection within first 30 day post-
transplantation and medium term graft survival [59]. Similarly, a study from Paris showed IgG3 
sub-class presence was associated with clinical biopsy-proven acute rejection and IgG4 was 
associated with sub-clinical rejection on protocol biopsies [60].  
Other classes of antibodies particularly IgM, despite being strongly complement-fixing, is not 
considered harmful [61-63]. However, recent case reports and small case series suggest they may 
modulate immune responses and are associated with rejection [64-66] and hence IgM class of 
HLA-specific antibodies warrants a detailed study, especially in relation to long term outcomes 
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rather than simply AAMR. In the setting of de novo HLA-specific antibody evolution, a recent study 
observed that the presence of IgM itself was not harmful but a co-existing IgG3 HLA-specific 
antibodies predicted poor graft survival [67].  
In our cohort of ninety-two highly sensitised patients, we studied for the presence of IgM donor 
specific antibodies at pre-transplant and at days 7, 14 and 30 post-transplant. IgM DSA were 
detected using Luminex-SAB kits (One lambda, CA). Detailed methods of IgM detection is 
described in previous publication [68]. We showed that over and above of current assays, a pre-
transplant IgM DSA is not helpful for the prediction of early antibody mediated rejection and renal 
allograft survival [68]. Presence of IgM DSA in the early post-transplant period was associated with 
poor renal allograft survival (Figure 7) in Kaplan Meier analysis. This suggests, further de novo 
responses or epitope spreading adds to the immunogenicity and thus is damaging. A new IgM DSA 
response against HLA that also has IgG pre-formed response may be new epitope-specific that 
antigen level assays cannot unleash. 
 
Figure 7 Kaplan Meier survival graph showing lower renal allograft survival in the presence 
of post-transplant (day-14) IgM DSA (p = 0.037) (unpublished data). 
4.4 Affinity Maturation 
Binding of antibodies to the corresponding antigen is the initial event followed by activation of 
various effector mechanisms. The strength of binding of these interactions is called affinity and 
can vary between individuals and within individuals for different antibody specificities and over 
time. Studies have shown that profiles of antibodies demonstrate heterogeneous affinity across 
the immune response and that higher affinity antibodies cause increased pathogenic responses 
[69-73]. There are no studies looked at this directly in context of kidney transplantation. A 
previous study speculated that higher binding strength of the interaction between the HLA 
epitope and HLA-specific antibody results in higher binding energy release, which brings 
conformational change to the immunoglobulin molecule, particularly to the complement fixing Fc 
portion. Thus it has been speculated that complement fixation could serve as a surrogate marker 
for higher affinity interactions [74]. The authors have further postulated that the reactivity and 
strength depend on antibody paratope interaction with eplets and other residues within 15 
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angstrom of the eplet in the structural epitopes. The larger area of interactions will depend on the 
difference between the given allele and the immunizing allele. The larger the area of interaction 
will give rise to stronger binding force/affinity. We have shown human monoclonal HLA-specific 
antibodies with the same concentration can have different affinities that influence binding on 
luminex assay [19]. Preliminary studies at our centre have shown that affinity of polyclonal HLA-
specific antibodies can differ widely (from E-03 to E-024 M), and different antibodies from the 
same patients have different affinities (Figure 8) [75]. The main challenge has been a high 
throughput assay minimising the non-specific bindings [21]. 
 
Figure 8 Binding kinetics of polyclonal HLA-specific antibodies from two different 
patients against HLA B40:02 proteins studied by surface plasmon resonance. 
Sensorgram shows binding response curve at reducing the concentration of 
antibodies; the solid line represents a mathematical fit to data using a heterogeneous 
analyte model (unpublished data and methodology- 
http://wrap.warwick.ac.uk/70964/).  
4.5 Other Characteristics 
Function and the effector response of antibodies could be altered by other properties such as 
glycosylation pattern of HLA-specific antibodies, polymorphisms of Fc gamma receptor on immune 
cells and interaction of Fc portion of HLA-specific antibodies [76]. Glycosylation status dictates 
flexibility of antibody molecule and thus may influence the interaction with antigen on a cell 
surface [77]. Similarly, Fc portion interactions with effector cells may differ depending on the Fc 
receptor's polymorphism on these cells and the affinity of the interactions. In a study of 1682 
patients, authors analysed the possible mechanisms of graft failure in 135 patients who 
experienced AMR. Seventy-three (54%) patients had complement activating antibodies (C3d-
positive DSA) as cause of graft failure. In remaining sixty-two (46%) patients, cause of worse graft 
survival was attributed to enhanced recruitment of Natural Killer (NK) cells by non-complement 
activating DSA due to missing self HLA I antigens. Proposed mechanism for chronic graft rejection 
include absence of inhibitory signals to NK cells due to missing HLA I antigens on the endothelial 
cells [78].  
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5. Novel Machine Learning Applications 
Methods that can analyse complex datasets independent of operator bias are potentially very 
important; especially now centres and registries are generating 10–15-year outcome data, which 
is surely going to be the gold standard for judging clinical success and inferring biologically 
important mechanisms. Therefore, in our cohort, we have used mathematical approaches to 
interrogate such clinical datasets, in particular, decision trees and random forests for risk 
prediction of antibody mediated rejection and graft survival. Using random forests, HLA 
mismatches, IgG MFI values and IgG4 subclass were shown to be associated with the highest risk 
for graft failure (Figure 9) [79] 
 
Figure 9 Based on 10 random forests, HLA mismatches, IgG MFI and IgG4 were 
associated with worse graft survival (adapted from Shaikhina et al. [79]). 
6. Dynamicity of HLA-Antibody Responses Following Transplantation 
In addition to individual characteristics of antibodies, dynamic behaviour after antigen 
exposure (transplantation) holds key to the underlying immune response and mechanism for 
injury and outcome. The limiting factor is the cost in such intensive monitoring of MFI values of 
HLA-specific antibodies following HLA-incompatible kidney transplantation. We have shown 
previously varied trends of MFI value. In some cases, there is a rapid rise followed by a rapid fall to 
an undetectable level. Dynamics of the DSA in the post-transplant period may help to predict 
antibody mediated rejection or graft survival later. In our cohort, we studied the falls of the DSA 
using mathematical models and found differences in the groups with AMR and no AMR [30]. We 
noticed that the falling MFI dynamics of HLA DSA after the peak value could not be described by a 
simple exponential law or, indeed, by a superposition of several exponential functions. Therefore, 
we have developed a generic form of a model that was able to capture the common patterns in all 
DSAs. Namely, we have described the DSA falls using 3rd order linear differential equations and 
found that the DSA decay times, as well as the general dynamic trends, were different in the two 
groups, i.e. with and without AMR. Three dimensional mathematical models (Figure 10) showed 
dissipations rates of DSAs faster in cases with AMR (Figure 10a). These models are novel ways to 
study dynamics of DSA behaviour and association with longer term outcomes are required prior to 
testing clinical application. 
 




Figure 10 Phase portraits of the three-dimensional system for two DSA time series, (a) 
from a patient in the AMR group and (b) from a patient in the no-AMR group. [30]; x is 
the function of time that describes MFI dynamics; ?̈?  and ?̈?are first and second 
derivatives of x, correspondingly. (adapted from [30]). 
The disappearance of antibodies from the serum in some patients is much quicker than the 
half-life of IgG molecule, and this observation suggests some active immune-modulating 
mechanism [80]. This could be due to the immune complex formation of HLA-specific antibodies 
to the soluble HLA molecule released from the transplanted organ [81], but current assays are 
unable to detect such complexes. Preliminary results from our centre have suggested lower HLA-
specific antibodies levels in cases with donor specific soluble HLA in the circulation following 
transplantation [82]. Another mechanism of neutralisation of HLA-specific antibodies could be by 
anti-idiotypic antibodies [83, 84]. 
7. Shortcomings of Current Approaches 
All these studies have shown that understanding the role of HLA antibodies in graft outcome is 
more complex than previously thought, with a series of relatively weak clinical associations, and 
the understandable, but erroneous, concentration on AAMR as a surrogate for adverse clinical 
outcome. Some studies have suggested the long-term outcome following early episode of AAMR is 
not always detrimental [85, 86] and thus studies relating characteristics with graft survival are 
important as studies using AAMR as an endpoint may be misleading. Hopefully, specific 
immunological assays will predict and explain the key immunological pathologies in 
transplantation. What is notable is that the recent long-term studies have not weakened the 
significance of the CDC assay – indeed have strengthened its significance. Although the assay was 
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designed to predict hyperacute rejection in our patients it is the best predictor, of the pre-
transplant tests available, of 10-year graft survival, given that our results show low levels of CDC 
positivity are tolerated. Perhaps some insights might arise from examination of what aspects of 
this venerable assay are particularly significant, developed by Terasaki in 1968 [9].  
Finally, however good our observation of antibody dynamics becomes, this is only part of the 
system that determines transplant outcome. We may be like the anthropologist trying to 
reconstruct an entire hominid species from a single tooth. Even if we can assemble a skeleton (the 
antibodies), that does not inevitably lead to an understanding of the soft tissues that support and 
command the skeleton (T and B lymphocytes, plasma cells, for example). 
8. Summary 
Advent of newer diagnostic and therapeutic modality has allowed safe transplantation in the 
presence of donor HLA-specific antibodies, up to low titre CDC positivity. However, the clinical 
outcome remains unpredictable with current assays, which take snap shots, and hence detailed 
analysis of other characteristics of antibodies are carried out by many centres (dissection analysis). 
This effort has been mainly focused on studying complement-fixing properties and recently on the 
analysis of sub-classes in relation to clinical outcome. Determination of the affinity of HLA-specific 
antibodies is only just undertaken, whilst other characteristics such as glycosylation, enhanced 
recruitment of innate cells in the absence of HLA I antigens and Fc portion binding to effector cells 
are being studied. Also, in recent times there is greater recognition and understanding the role 
antibodies directed against minor histocompatibility and non–HLA antigens. Developing better 
assays and studying detailed characteristics of antibody function and biophysical properties may 
give better composite biomarkers to predict rejection and graft failure in the sensitised patients 
and thus allow safer HLA-incompatible organ transplantation and will require unbiased machine 
learning analysis of large datasets. 
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